In The New England Journal of Medicine’s April 2022 edition, researchers “randomly assigned Black and Latinx adults with moderate-to-severe asthma to use a patient-activated, reliever-triggered inhaled glucocorticoid strategy” along with “usual care.” Those not assigned the treatment were instructed to continue their usual care. Of the 1201 adults in the study, the 600 in the intervention group showed “lower rate of severe asthma exarcerbations.”
For more information, and to view the study, click here.